Hospital Universitario De Cabuenes
- Address
- Calle Los Prados 395, 33203 Gijón, Spain
Cardiovascular Research
At Hospital Universitario De Cabuenes, the Cardiovascular Diseases program focuses on patients with acute coronary syndrome and broader atherosclerotic cardiovascular disease, including elevated lipoprotein(a). These studies are designed to assess whether new treatments can lower the risk of major heart and blood vessel events and improve long-term outcomes.
- Evaluating therapies aimed at reducing major cardiovascular events after a heart attack
- Studying treatment options for people with atherosclerotic cardiovascular disease and elevated lipoprotein(a)
- Comparing new approaches with placebo to better protect against heart-related complications
This area reflects a strong interest in preventing serious outcomes such as heart attack, stroke, and urgent coronary procedures.
Digestive Disease Studies
The Gastroenterology department is also active in Digestive System Diseases, with research centered on ulcerative colitis. The trials in this field are exploring whether emerging therapies can improve clinical response and help people living with active inflammatory bowel disease.
- Testing new treatment strategies for moderately to severely active ulcerative colitis
- Assessing whether investigational therapies can improve symptoms and disease control
- Supporting better management of chronic intestinal inflammation
This work highlights ongoing efforts to expand treatment options for patients with difficult-to-control bowel disease.
Hematology and Myeloma Research
Research in Hemic and Lymphatic Diseases at this site includes studies in multiple myeloma and relapsed/refractory multiple myeloma. These trials are focused on evaluating newer immunotherapy approaches and understanding how well they control disease in patients who have already received prior treatments.
- Comparing novel therapies for relapsed or refractory multiple myeloma
- Evaluating clinical effectiveness in patients previously treated with multiple drug classes
- Measuring deeper disease responses, including the absence of measurable residual disease
The Hospital Universitario De Cabuenes contributes to research aimed at improving outcomes for patients with advanced blood cancers.
Oncology and Advanced Therapy Evaluation
Within Neoplasms, the site participates in trials that examine innovative cancer treatments designed to improve disease control in hard-to-treat conditions. The main emphasis is on assessing whether new therapies can offer better results for patients with advanced malignancies, especially when standard options have been exhausted.
- Investigating new treatment options for difficult-to-treat cancer settings
- Exploring whether advanced therapies can extend progression-free survival
- Supporting research into better care for patients with relapsed disease
This reflects a broader commitment to testing promising approaches that may improve cancer outcomes and quality of care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Cabuenes
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acenocoumarol | 1 | Unknown | 2024-11-19 | 2024-11-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.